Hester Biosciences profit and loss

Latest FY26

Revenue: ₹333cr+6.9% on FY25
EBITDA: ₹86.7cr+41.9% on FY25
Net profit: ₹57.5cr+99.4% on FY25
EPS: ₹67.57+99.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	326	333	311	305	266	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	9.0	9.7	3.9	10.6	15.2
	335	342	315	315	281
	70.8	70.6	63.9	54.3	53.0
	16.8	15.7	17.6	32.8	29.7
	−11.0	−4.4	6.8	8.7	−5.3
	62.3	62.7	62.4	64.1	56.0
	12.2	10.9	12.7	19.8	9.3
	21.7	18.9	16.8	17.2	20.7
	100	101	99.3	90.9	82.0
	273	276	280	288	245
	86.6	86.7	61.1	53.7	50.6
	64.9	67.8	44.3	36.5	29.9
Profit
	61.7	66.5	35.5	27.3	35.7
	88.3	2.9	0.0	0.0	0.0
	150	69.5	35.5	27.3	35.7
	17.5	15.1	12.2	10.7	11.3
	2.9	3.2	−1.5	0.1	0.8
	20.4	18.4	10.7	10.8	12.1
	7.4	6.4	4.1	4.6	4.4
	137	57.5	28.8	21.2	28.0
	130	51.1	24.7	16.6	23.6
	−2.6	−2.3	0.1	−0.0	1.6
	134	55.2	28.9	21.1	29.7
	136	55.6	27.5	18.9	26.6
	0.7	1.8	1.3	2.3	1.4
Per share
	₹160.95	₹67.57	₹33.89	₹24.88	₹32.96
	₹160.95	₹67.57	₹33.89	₹24.88	₹0.00
Other comprehensive income — detail
	−2.6	−2.3	0.1	—	—
	—	−0.0	−0.5	−0.1	0.1
	0.0	−0.0	−0.1	—	—
	—	—	—	−0.0	0.0
	−2.7	−2.3	0.5	0.0	1.5
	134	53.3	27.6	18.9	28.3
	0.8	1.9	1.3	2.3	1.4
Per share — as-filed variants
	₹160.95	₹67.57	₹33.89	₹24.88	₹32.96
	₹160.95	₹67.57	₹33.89	₹24.88	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	249	251	223	209	189
	76.5%	75.4%	71.6%	68.5%	70.9%
Adjusted (ex-exceptional items) — derived
	61.7	66.5	35.5	27.3	35.7
	88.3	2.9	0.0	0.0	0.0
	60.6	55.3	28.8	21.2	28.0
	₹71.29	₹65.03	₹33.89	₹24.88	₹32.96

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,909 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	266.1	304.5	311.1	332.6	325.7
Other Income	15.2	10.6	3.9	9.7	9.0
Total Income	281.2	315.2	315.0	342.3	334.7
Expenses
+ Cost of Materials Consumed	53.0	54.3	63.9	70.6	70.8
+ Purchases of Stock-in-Trade	29.7	32.8	17.6	15.7	16.8
+ Changes in Inventories	-5.3	8.7	6.8	-4.4	-11.0
+ Employee Benefit Expense	56.0	64.1	62.4	62.7	62.3
+ Finance Costs	9.3	19.8	12.7	10.9	12.2
+ Depreciation & Amortisation	20.7	17.2	16.8	18.9	21.7
+ Other Expenses	82.0	90.9	99.3	101.3	100.3
Total Expenses	245.5	287.8	279.6	275.8	273.1
EBITDA	50.6	53.7	61.1	86.7	86.6
EBIT	29.9	36.5	44.3	67.8	64.9
Profit
PBT before Exceptional Items	35.7	27.3	35.5	66.5	61.7
+ Exceptional Items	0.0	0.0	0.0	2.9	88.3
Pretax Income	35.7	27.3	35.5	69.5	150.0
+ Current Tax	11.3	10.7	12.2	15.1	17.5
+ Deferred Tax	0.8	0.1	-1.5	3.2	2.9
Tax Expense	12.1	10.8	10.7	18.4	20.4
+ Share of Associates & JVs	4.4	4.6	4.1	6.4	7.4
Net Income	28.0	21.2	28.8	57.5	136.9
+ Net Income — Continuing Ops	23.6	16.6	24.7	51.1	129.6
+ Other Comprehensive Income	1.6	-0.0	0.1	-2.3	-2.6
Total Comprehensive Income	29.7	21.1	28.9	55.2	134.3
Net Income to Common	26.6	18.9	27.5	55.6	136.2
Minority Interest	1.4	2.3	1.3	1.8	0.7
Per Share
Basic EPS	32.96	24.88	33.89	67.57	160.95
Diluted EPS	0.00	24.88	33.89	67.57	160.95
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.1	-2.3	-2.6
+ Items NOT to be Reclassified to P&L	0.1	-0.1	-0.5	-0.0	—
+ Tax on Items NOT to be Reclassified	—	—	-0.1	-0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.0	—	—	—
+ Items to be Reclassified to P&L	1.5	0.0	0.5	-2.3	-2.7
Comprehensive Income — Owners of Parent	28.3	18.9	27.6	53.3	133.6
Comprehensive Income — Non-controlling Interests	1.4	2.3	1.3	1.9	0.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	32.96	24.88	33.89	67.57	160.95
Diluted EPS — Continuing Operations	0.00	24.88	33.89	67.57	160.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	188.6	208.7	222.8	250.6	249.2
Gross Margin %	70.88	68.52	71.61	75.36	76.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	35.7	27.3	35.5	66.5	61.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	2.9	88.3
Net Income Adj (tax-effected)	28.0	21.2	28.8	55.3	60.6
EPS Adj	32.96	24.88	33.89	65.03	71.29
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	8.5	8.5	8.5	8.5	8.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.